title: [Relationship between prothrombin time international normalized ratio and thrombo test (%)].
abstract: OBJECTIVE
  The optimal therapeutic range for laboratory evaluation of oral anticoagulant therapy is now defined by the prothrombin time international normalized ratio (PT-INR). However, the thrombo test (TT), an alternative method to measure intensity of anticoagulation, is also currently used throughout Japan. The relationship between PT-INR and TT (%) has yet to be clarified. This study investigated the relationship between PT-INR and TT (%).
  
  
  METHODS
  The PT-INR and TT (%) were simultaneously measured of 505 consecutive samples from patients treated with warfarin in our hospital. Fourteen functions were used for regression analyses: a fractional function (Y = a/X + b), a square root function (Y = aX0.5 + b), a natural logarithmic function (Y = a.lnX + b), a power series function (Y = aXb), a quotient function (Y = abX), and polynomial functions [Y = anXn + an - 1Xn - 1 +......+ a1X1 + b, (1 < or = n < or = 9)]. The results were confirmed by the same methods in 383 samples and 296 samples from another two laboratories.
  
  
  RESULTS
  The power series function showed the most significant (p < 0.0001) and highest adjusted R2 (0.858) correlation, with a regression formula of TT (%) = e4.48 (PT-INR)-2.09 in our laboratory. Using the same analyses, the power series function also showed the most significant and highest adjusted R2 in samples from the other two laboratories.
  
  
  CONCLUSIONS
  This study showed that a power series function is the most appropriate for expressing the relationship between PT-INR and TT (%) among the 14 functions. The function between PT-INR and TT (%) is mainly derived from the relationship between TT (%) and TT (sec). Both internal validity and external validity confirmed the relationship between PT-INR and TT (%).
authors.affiliation: Department of Cardiology, Japanese Red Cross Kumamoto Hospital, Nagamineminami 2-1-1, Kumamoto, Kumamoto 862-8520.
authors.forename: Y
authors.initials: Y
authors.lastname: Numata
authors.forename: Y
authors.initials: Y
authors.lastname: Ogata
authors.forename: K
authors.initials: K
authors.lastname: Arao
authors.forename: Y
authors.initials: Y
authors.lastname: Mizumasa
authors.forename: T
authors.initials: T
authors.lastname: Wakita
authors.forename: H
authors.initials: H
authors.lastname: Haruguchi
authors.forename: H
authors.initials: H
authors.lastname: Araki
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: K
authors.initials: K
authors.lastname: Mawatari
authors.forename: K
authors.initials: K
authors.lastname: Shimada
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D001780:Blood Coagulation Tests; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D012015:Reference Standards; D012044:Regression Analysis; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D014859:Warfarin